Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 8/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.43 |
| ▸ | PDE2A | O00408 | 6/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL968420 | 0.93 | PDE10A (0.55) | PDE10AALOX5PDE2APTPN1 | |
| SCHEMBL970001 | 0.88 | PDE10A (0.46) | PDE10APDE2ACYP11B1 | |
| SCHEMBL970420 | 0.78 | PDE10A (0.55) | PDE10APDE2ACYP11B1 | |
| SCHEMBL972907 | 0.77 | CSF1R (0.43) | PDE10APDE2AMEN1KMT2A | |
| SCHEMBL968810 | 0.76 | PDE10A (0.62) | PDE10APDE2ACYP11B1 | |
| SCHEMBL968377 | 0.74 | PDE10A (0.46) | PDE10APDE2AMAPTCYP11B1 | |
| SCHEMBL970074 | 0.72 | PDE10A (0.52) | PDE10APDE2ACYP11B1 | |
| SCHEMBL971047 | 0.72 | RAB9A (0.58) | PDE10APDE2APTPN1MEN1MAPT | |
| SCHEMBL972747 | 0.71 | PDE10A (0.51) | PDE10APDE2A | |
| SCHEMBL11161726 | 0.71 | PDE10A (0.36) | PDE10AALOX5MEN1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875618-B2 | 8-chloro-3,4-dimethyl-1-(2- methylphenyl)imidazo[1,5- a]quinoxaline; inhibitors of phosphodiesterase 10; for treatment of central nervous system disorders (cognitive deficits, social phobia, reduced vigilance, obesity and psychosis) | WYETH (US) | 2011-01-25 | — | — | US | disclosed |
| EP-2225248-A1 | ARYL AND HETEROARYL FUSED IMIDAZO[1,5-A]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | Wyeth LLC (US) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009070584-A1 | ARYL AND HETEROARYL FUSED IMIDAZO[1,5-A]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | WYETH (US) | 2009-06-04 | — | — | WO | disclosed |
| US-20090143367-A1 | ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | ELBION GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143367-A1 | ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | PDE12, PDE5A, PDE10A | PDE10A 3/4885ALOX5 1095/4885PDE2A 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.